Introduction
Until recently, pulse oximeters have been limited by the fact that they use two wavelengths of light to empirically estimate arterial oxygen saturation, displayed as SpO 2 . With only two wavelengths, the pulse oximeter must 'assume' that the only light absorbers in the blood are oxyhemoglobin and reduced hemoglobin (Hb). This assumption is frequently violated, resulting in serious SpO 2 errors. Although multiwavelength pulse oximeters have been the subject of research in the past, the first multiwavelength instruments did not reach the commercial medical market until 2005. The new 'Rainbow Technology' pulse oximeters developed by Masimo Corp. have permitted the noninvasive measurement of carboxyhemoglobin (COHb), methemoglobin (MetHb), and now total hemoglobin (Hbt). The purpose of this article is to review the history, development, and clinical application of multiple wavelength pulse oximetry through the present date.
Background: limitations of conventional pulse oximetry
Since its invention by Aoyagi in 1975 , the pulse oximeter has become the most prevalent monitor of blood oxygenation in the operating room and other critical care settings [1] . As the use of pulse oximetry expanded rapidly in the 1980s, some of its errors and limitations gradually became apparent. One source of errors derives from the fact that conventional pulse oximetry uses only two wavelengths of light to estimate the ratio of arterial oxyhemoglobin to Hbt, displayed as SpO 2 . To calculate this estimate with only two light wavelengths, the pulse oximeter uses an algorithm based on the assumption that there are only two light absorbers in arterial blood: reduced Hb and oxyhemoglobin. Whenever this two light absorbers assumption is violated, the pulse oximeter may be subject to serious errors.
Laboratory and clinical data demonstrating dyshemoglobin errors Barker and Tremper [2] showed in 1987 that in the presence of COHb, the conventional pulse oximeter can neither detect the dyshemoglobin nor correctly determine SpO 2 in its presence. Figure 1 [2] illustrates the behavior of a conventional pulse oximeter in the presence of increasing levels of COHb. The pulse oximeter 'sees' COHb as though it were mostly (90%) oxyhemoglobin. Thus, a patient with life-threatening carbon monoxide poisoning will exhibit nearly normal pulse oximeter readings. The same authors found in 1989 that twowavelength pulse oximeters are also inaccurate in the presence of MetHb, which is induced by many of the drugs that we commonly use [3] . Figure 2 [3] shows readings of conventional pulse oximetry during increasing levels of MetHb. At higher MetHb levels, the SpO 2 reading is forced towards a value of 85%. Incidentally, the high MetHb levels (60%) shown in this figure were induced with intratracheal benzocaine spray, a common clinical problem that is discussed further below.
Case reports of both of these dyshemoglobins have verified the pulse oximeter errors found in these two early studies. An interesting case report of methemoglobinemia caused by nitrites in herbal medicines exemplifies this behavior [4] . Other abnormal Hbs, such as Hemoglobin Bassett, can also produce erroneous SpO 2 readings [5] . The effect of sickle hemoglobin (Hb-S) upon two-wavelength pulse oximetry remains controversial, with some studies indicating large errors [6] and others showing minimal effect [7] . Pulse oximeter errors produced by intravenous (i.v.) dyes have been well documented in both volunteer studies [8] and case reports [9] . Dyes of a blue color (methylene blue, isosulfan blue) consistently cause erroneously low readings on two-wavelength pulse oximeters. Arguments about whether these pulse oximeters measure fractional or functional saturation are actually moot. In the absence of dyshemoglobins or dyes, they measure both (functional and fractional saturations are the same), whereas in the presence of dyshemoglobins or dyes, they measure neither.
Early efforts in multiwavelength pulse oximetry
Before 2006, there were a few preliminary investigations into the possibilities of multiwavelength pulse oximetry. Aoyagi [10] , who invented the pulse oximeter, performed experiments with three-wavelength sensors in 2002. Although his purpose in using an additional wavelength was simply to improve the accuracy of the SpO 2 value, he 806 Technology, education, training and information systems 
Clinical studies and case reports of SpCO and SpMet
Laboratory volunteer studies can determine the accuracy and reliability of a new monitor in healthy individuals under controlled conditions, but they can neither predict performance in clinical conditions nor establish effects upon patient care and outcome. We must rely upon clinical studies and case reports, and a number of these have been published in the past 2 years. Coulange et al.
[15] measured SpCO from Rad-57 and simultaneous values of COHb% from venous blood CO-oximetry in smoke inhalation victims. In data from 12 patients, they found a bias of À1.5% and a precision of 2.5%. Layne et al.
[16] measured SpCO and COHb% (Avox 400 COoximeter; Avox, San Antonio, Texas, USA) in 130 outpatients, both smokers and nonsmokers. They found a bias of À0.65% and a precision of 1.8%, in a COHb range from zero to 31%. Both the above clinical studies found SpCO measurement uncertainties essentially the same as the Barker laboratory volunteer study [14] .
There are numerous published clinical case reports of the use of Rad-57 to detect and measure COHb levels. Several authors have used SpCO as a screening tool to identify smokers and track smoking cessation [17] [18] [19] .
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Figure 3 A Masimo 'Rad-57' handheld multiwavelength pulse oximeter. Displays SpCO and SpMet, as well as SpO 2 and pulse rate
Another promising application for a handheld multiwavelength device is in fire fighting units and Emergency Medical Services (EMS) responders. Hostler et al. [20 ] showed that SpCO could be used as a diagnostic when firefighters respond to carbon monoxide alarm activations. They found that patients requiring transport to the emergency department had mean SpCO levels of 27.8%, whereas patients not in need of treatment had mean levels of 3.2%. A similar study of 149 patients by the New York Fire Department concluded that 'The Rad-57 noninvasive CO-oximeter can be used as a screening tool to uncover cases of CO poisoning in which the diagnosis is not suspected' [21] . Firefighters themselves have been screened with SpCO in other investigations [22] . An interesting case report described a British submarine crewman who fought an onboard fire while under the polar icecap, and his COHb level of 28% was diagnosed and monitored with Rad-57 [23 ] . Case reports from the emergency department have shown the value of continuous SpCO monitoring in tracking the treatment progress of carbon monoxide poisoning victims, as well as the detection of carbon monoxide poisoning in unsuspected cases [24 ,25,26,27 ] . Figure 4 shows an excellent example of SpCO trend monitoring and response to treatment of an 81-year-old woman who was trapped in a house fire [24 ] .
Clinical case reports of Rad-57 being used to detect and monitor methemoglobinemia are also beginning to accumulate in the literature. A significant number of reported life-threatening MetHb cases involve the use of topical benzocaine [28] . As reported by Ash-Bernal et al. [29] , a large number of other commonly used drugs can also induce MetHb, and the problem has undoubtedly been underdiagnosed in the past. Macknet et al. [30] presented a case of severe benzocaine-induced methemoglobinemia during transesophageal echocardiography, in which Rad-57 was used to make the diagnosis and monitor treatment with methylene blue. Barker and Annabi [31 ] reported a similar case in the operating room, following benzocaine topicalization for awake intubation. In both these cases, the multiwavelength pulse oximeter played a major role in diagnosis and treatment, whereas in-vitro laboratory values were too far delayed to guide treatment.
The current versions of the Masimo Rad-57 and Radical-7 have two limitations that the skilled user should understand. First, they now use a conventional two-wavelength 'red over infrared' algorithm to calculate the SpO 2 value. Thus, when there are significant levels of either COHb or MetHb, the displayed SpO 2 will be subject to the same errors described above and in references [2] and [3] . Of course, the presence of a large SpCO or SpMet value would alert the user to this SpO 2 error, which conventional pulse oximetry would not do. The second limitation is the existence of 'crosstalk' between the MetHb and COHb measurement channels. That is, in the presence of significant MetHb levels, the instrument will display a falsely elevated SpCO value while it also displays a correct SpMet value. This situation is detected by the software, and Rad-57/Radical-7 will display an error message indicating that the SpCO may not be accurate. [32 ] published the first clinical validation study, in which 30 surgical patients as well as 18 healthy volunteers were monitored with the Radical-7. The volunteers followed a hemodilution protocol in which one unit of blood was withdrawn and replaced with isotonic saline. Arterial blood was sampled periodically and analyzed for Hbt by a Radiometer ABL-735 CO-oximeter (Radiometer America, Westlake, Ohio, USA). These values were compared with the simultaneous pulse CO-oximeter measurements of hemoglobin (SpHb), as shown in Fig. 5 [32 ]. In a range of Hbt values from 4.4 to 15.8 g/dl, this comparison revealed a bias and precision of 0.03 and 1.12 g/dl, respectively.
A very interesting presentation at the 2008 World Congress of Anesthesiology described a case in which casual screening with the Radical-7 revealed an abnormally low SpHb (11 g/dl) in a 72-year-old man [33 ] . This led to further tests, which yielded an early diagnosis of an asymptomatic esophageal carcinoma. The early diagnosis led to complete surgical excision and probable cure of a disease with a high mortality. The noninvasive measurement of Hbt by pulse oximetry is very new, and we can expect to see more case reports and clinical application studies in the near future. Obviously, this is an exciting new development with great clinical potential.
Conclusion
In 2008, multiwavelength pulse oximetry is capable of the continuous, noninvasive measurement of MetHb, COHb, and Hbt. Technology has finally made real progress in correcting one of the chief weaknesses of pulse oximetry: performance in the presence of abnormal Hb species [2, 3] . Clinical studies and case reports have already documented the importance of these new developments. Perhaps more importantly, after more than 30 years of pulse oximetry, we may see the opening of a new frontier -the noninvasive measurement of the concentrations of other substances in the blood. If the current technology from Masimo Corp. can measure COHb, MetHb, and SpHb, it is natural to ask what is next. We can certainly hope to measure other abnormal Hb species: fetal-Hb and sickle-Hb are obvious examples. Beyond this logical extension, could multiwavelength pulse oximetry lead to the measurement of plasma electrolytes, or perhaps glucose? Only time and technology will tell.
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